ReviewPharmaceuticals (Basel, Switzerland)2014
The fungal defensin family enlarged.
Review in Pharmaceuticals (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Licosin, a multifunctional defensin peptide originated from the clinical fungusFrontiers in microbiology · 2026Article
- Piggybacking on nature: exploring the multifaceted world of porcine β-defensins.Veterinary research · 2025Review
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Discovery of Five Classes of Bacterial Defensins: Ancestral Precursors of Defensins from Eukarya?ACS omega · 2024Article
- Novel technologies uncover novel 'anti'-microbial peptides inPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Article
- Production of Helvolic Acid in Metarhizium Contributes to Fungal Infection of Insects by Bacteriostatic Inhibition of the Host Cuticular Microbiomes.Microbiology spectrum · 2022Article
- An Overview of the Potentialities of Antimicrobial Peptides Derived from Natural Sources.Antibiotics (Basel, Switzerland) · 2022Review
- A Fungal Defensin Inhibiting Bacterial Cell-Wall Biosynthesis with Non-Hemolysis and Serum Stability.Journal of fungi (Basel, Switzerland) · 2022Article
- Antimicrobial Peptides: An Update on Classifications and Databases.International journal of molecular sciences · 2021Review
- A Fungal Defensin Targets the SARS-CoV-2 Spike Receptor-Binding Domain.Journal of fungi (Basel, Switzerland) · 2021Article
- Fungal evolution: cellular, genomic and metabolic complexity.Biological reviews of the Cambridge Philosophical Society · 2020Article
- Article
- New fungal defensin-like peptides provide evidence for fold change of proteins in evolution.Bioscience reports · 2017Article
- Convergent evolution of defensin sequence, structure and function.Cellular and molecular life sciences : CMLS · 2017Review
- Hitting the sweet spot-glycans as targets of fungal defense effector proteins.Molecules (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungi are an emerging source of peptide antibiotics. With the availability of a large number of model fungal genome sequences, we can expect that more and more fungal defensin-like peptides (fDLPs) will be discovered by sequence similarity search. Here, we report a total of 69 new fDLPs encoded by 63 genes, in which a group of fDLPs derived from dermatophytes are defined as a new family (fDEF8) according to sequence and phylogenetic analyses. In the oleaginous fungus Mortierella alpine, fDLPs have undergone extensive gene expansion. Our work further enlarges the fungal defensin family and will help characterize new peptide antibiotics with therapeutic potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.